Abstract
The association between COVID-19 vaccination and thromboembolic events has gar-nered significant research attention, particularly with the advent of vaccines based on adenoviral vectors, including AstraZeneca's and Johnson & Johnson's. This review un-derscores the uncommon occurrence of blood clotting events, including venous throm-boembolism (VTE), arterial thromboembolism (ATE), and vaccine-induced thrombotic thrombocytopenia (VITT), following COVID-19 vaccination. Although these complica-tions are extremely rare compared to the heightened risk of thrombosis from COVID-19 infection, elements like age, biological sex, type of vaccine and underlying health conditions may contribute to their development. Current guidelines emphasize early detection, individualized risk assessment, and the use of anticoagulation therapy to mitigate risks. Despite these rare events, the overwhelming evidence supports the con-tinued use of COVID-19 vaccines, given their proven efficacy in reducing severe illness and mortality. Ongoing research is essential to further refine preventive and therapeu-tic strategies, particularly for at-risk populations.

This publication has 28 references indexed in Scilit: